Recap and Forecast 22/23

Voluntary reporting of sustainability targets and progress strengthens customer relationships through transparency and accountability    

Economic success and ambitious sustainability goals can be achieved in conjunction with one another 

Aiming to be completely climate-neutral by 2050, Vetter joins the Science Based Targets Initiative (SBTi)

Our values make us as pharmaceutical service provider, employer, and family business unique. Find out what stands behind the Vetter name.

Elevated commitment to CO2 accounting in accordance with globally recognized greenhouse gas protocol  Achieved ecovadis Platinum status: Vetter is among the one percent most sustainable companies worldwide 

Sustainability goals are backed up with concrete measures of success.
 

 

 

Our US-based clinical development site offers comprehensive services and know-how for a wide variety of compounds, including process development, cGMP clinical batches, regulatory support and more. This state-of-the-art facility features 50K square feet of specialized lab space, 2 clean rooms, and the expertise of over 100 clinical development professionals.

- Association grants Vetter extraordinary membership  

- vfa recognizes the importance of pharmaceutical service providers in drug development and production  

- Vetter serves on key vfa committees 

We can package a wide variety of drug delivery systems and formats and offer several services such as cartoning (all paper), blistering, labeling, serialization and aggregation , testing. Our dedicated engineering department specializes in developing novel packaging processes for safety device and delivery systems like pens and autoinjectors.

- Vetter successfully brought eight customer drugs to market after supporting them through the development phases 

- As an established leader in commercial fill and finish, Vetter has evolved as a trusted provider of drug product development services 

- New molecules candidates brought to Vetter in the clinic receive strategic counsel and experienced support to guide their path to market and beyond 

How to prepare for the device assembly & packaging process

- Successful inspection completed at clinical site 

- Inspectors were impressed with systems and processes 

- Austrian site supports manufacturing and quality control of Human Investigational Medicinal Products 

Get your product to the clinic with confidence

The shift from preclinical to clinical development is a critical step in the development of your drug product.


During this transition, you not only have to significantly upscale production of your product, but also make many strategic decisions that will lay important groundwork for your regulatory submission, commercial production of your product, and many other key components of your products life-cycle.


This eBook will help you build a plan that not only streamlines your products path to the clinic but also sets you up for long-term development and market success - starting with a proven 6-step process for filling your critical clinical batch.

Ongoing investments in the supply chain for complex injectable medications
- Committed to sustainable growth and long-term planning
- Dedicated to making investments to support increased customer demand
- Maintain efficiency and quality in development and manufacturing processes 

For over four decades, pharma and biotech companies around the world have relied on us to put their parenteral medications on a path to success. We’re proud to help our customers advance their valuable products with innovative services, cutting-edge technology, and flexible, robust, scalable processes that set our partnership apart.

Already 14 customer fills completed in the first quarter of 2023  

More than ten successfully completed customer audits confirm high quality and process standards 

Vetter underpins commitment to customers in drug development with expansion

Vetter (Ravensbury, Germany), the aseptic filling and packaging CDMO has signed up to the UN Global Compact Network. 

Peter Soelkner, Managing Director at Vetter, sat down with Raman Sehgal of the “Molecule to Market” podcast to share his personal background, the history of Vetter, and the ambitious goals the company is striving towards today.

Clinical development pipeline is essential to global business strategy
Vetter Development Service offers comprehensive expertise for in-human trial material

New facility in Austria expands clinical manufacturing capacity 

The rising demand for at-home self-administered therapies has made patient-friendly formats, such as autoinjectors, a necessity for drug manufacturers. However, the intricacies of manufacturing these devices pose significant challenges. This presentation offers valuable insights into planning the device assembly and packaging process, enabling drug owners to navigate this evolving landscape with confidence and efficiency.

Opportunities for contract development and manufacturing organisations (CDMOs) in China continue to grow but many questions remain over what the future of the sector will look like in the world's second largest pharmaceutical market.

Bundling of competencies optimizes workflow of customer projects.

All German sites of the pharmaceutical service provider will be supplied with green electricity.